The acquisition of Unetixs Vascular’s detection and diagnostics products complements and strengthens the existing Opto Circuits (I) Ltd. product portfolio investment in Criticare Systems, Inc.’s vital signs monitoring line and pulse oximetry sensors. Unetixs Vascular is a leader in products aimed at the detection of peripheral arterial disease (PAD), a condition that is affecting a growing portion of the population in both the developed world and in emerging economies.
Opto Circuits/Criticare Systems is set to accelerate the launch of Unetixs products into key global markets.
“The new Revo® line was a major factor in our pursuit of acquiring Unetixs, which is a unique product with no real competition. In addition, the recently released VascuLink® networking software adds a new dimension for Unetixs’ office-based products. We believe the Revo® has big potential for us in the global markets and will be high on our focus of market capabilities moving forward,” stated Vinod Ramnani, Chairman and Managing Director of Opto Circuits India.
“The acquisition creates high synergies between Criticare’s vital signs monitors and Unetixs’ vascular diagnostics systems, opening up new channels for both companies in the global acute and primary-care markets,” stated Joseph LaPorta, CEO of Criticare Systems Inc. and the newly appointed CEO of Unetixs Vascular Inc.
“Unetixs is uniquely placed in the hospital market and their attention to what is needed is a real credit to their ability to deliver clinical accuracy with the larger MultiLab® Series of products. Unetixs’ products can be found in most luminary hospitals and teaching institutions across the United States,” stated Joseph LaPorta.
SOURCE Criticare Systems, Inc.